Vera Therapeutics, Inc. (VERA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $35.31 (-0.83%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 11, 2025 | Laura Chico | Wedbush | $33.00 | -6.6% |
| Dec 8, 2025 | Gavin Clark-Gartner | Evercore ISI | $97.00 | +174.7% |
| Jun 3, 2025 | Greg Harrison | Scotiabank | $65.00 | +84.1% |
| Mar 21, 2024 | Laura Chico | Wedbush | $34.00 | -3.7% |
| Jan 26, 2024 | Ryan Deschner | Raymond James | $37.00 | +4.8% |
| Dec 18, 2023 | Ryan Deschner | Raymond James | $29.00 | -17.9% |
Top Analysts Covering VERA
VERA vs Sector & Market
| Metric | VERA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.10 | 2.24 | 2.41 |
| Analyst Count | 10 | 8 | 18 |
| Target Upside | +119.7% | +1150.1% | +14.9% |
| P/E Ratio | -7.96 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1M | $1M | $1M | 1 |
| 2026-09-30 | $9M | $9M | $9M | 1 |
| 2026-12-31 | $41M | $41M | $41M | 1 |
| 2027-03-31 | $27M | $27M | $27M | 1 |
| 2027-06-30 | $38M | $38M | $38M | 1 |
| 2027-09-30 | $54M | $54M | $54M | 1 |
| 2027-12-31 | $83M | $83M | $83M | 1 |
| 2028-12-31 | $690M | $690M | $690M | 9 |
| 2029-12-31 | $532M | $1.09B | $2.24B | 4 |
| 2030-12-31 | $704M | $1.45B | $2.97B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.44 | $-1.40 | $-1.34 | 4 |
| 2026-09-30 | $-1.36 | $-1.36 | $-1.36 | 1 |
| 2026-12-31 | $-1.16 | $-1.16 | $-1.16 | 2 |
| 2027-03-31 | $-1.14 | $-1.14 | $-1.14 | 2 |
| 2027-06-30 | $-0.98 | $-0.98 | $-0.98 | 1 |
| 2027-09-30 | $-0.75 | $-0.75 | $-0.75 | 1 |
| 2027-12-31 | $-0.37 | $-0.37 | $-0.37 | 2 |
| 2028-12-31 | $-1.96 | $1.23 | $6.89 | 8 |
| 2029-12-31 | $1.41 | $4.25 | $10.07 | 6 |
| 2030-12-31 | $2.26 | $6.80 | $16.10 | 6 |
Frequently Asked Questions
What is the analyst consensus for VERA?
The consensus among 10 analysts covering Vera Therapeutics, Inc. (VERA) is Buy with an average price target of $77.60.
What is the highest price target for VERA?
The highest price target for VERA is $97.00, set by Gavin Clark-Gartner at Evercore ISI on 2025-12-08.
What is the lowest price target for VERA?
The lowest price target for VERA is $29.00, set by Ryan Deschner at Raymond James on 2023-12-18.
How many analysts cover VERA?
10 analysts have issued ratings for Vera Therapeutics, Inc. in the past 12 months.
Is VERA a buy or sell right now?
Based on 10 analyst ratings, VERA has a consensus rating of Buy (2.10/5) with a +119.7% upside to the consensus target of $77.60.
What are the earnings estimates for VERA?
Analysts estimate VERA will report EPS of $-1.40 for the period ending 2026-06-30, with revenue estimated at $1M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.